BackDeep Medicine Acquisition - Tradeable Rights - Oct 2026 Overview

Deep Medicine Acquisition - Tradeable Rights - Oct 2026 Current Assets

Deep Medicine Acquisition - Tradeable Rights - Oct 2026's current assets is $14M.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$14.38M
21.16% YoYΔ $-3.86M vs prior year quarter

Peer average / median

Loading

Deep Medicine Acquisition - Tradeable Rights - Oct 2026 Current Assets History

Loading

Deep Medicine Acquisition - Tradeable Rights - Oct 2026 vs. peers: Current Assets Comparison

Loading

Deep Medicine Acquisition - Tradeable Rights - Oct 2026 Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Deep Medicine Acquisition - Tradeable Rights - Oct 2026 (DMAQR) FAQ

Deep Medicine Acquisition - Tradeable Rights - Oct 2026 posts a current assets of $14M as of March 2026. That compares with $18M in the prior-year period — down 21.2% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Deep Medicine Acquisition - Tradeable Rights - Oct 2026's current assets was $18M. The latest reading is $14M — a 21.2% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Current Assets is one piece of Deep Medicine Acquisition - Tradeable Rights - Oct 2026's financial statement story. At $14M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for DMAQR's current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Deep Medicine Acquisition - Tradeable Rights - Oct 2026's other metric pages and overview cover the third.